(Pharma-Essence) Announcement: Board of Directors Resolution to Approve Q1 FY115 Consolidated Financial Report

1. Date of Board of Directors meeting or resolution: 115/05/11. 2. Date of Audit Committee approval: 115/05/11. 3. Reporting period for financial report or annual self-assessed financial information (Start Date~End Date): 115/01/01~115/03/31. 4. Accumulated operating revenue from January 1 to the current period (thousands of NT$): 918,059. 5. Accumulated gross profit (or loss) from January 1 to the current period (thousands of NT$): 731,200. 6. Accumulated operating income (or loss) from January 1 to the current period (thousands of NT$): 142,602. 7. Accumulated profit (or loss) before tax from January 1 to the current period (thousands of NT$): 241,072. 8. Accumulated net profit (or loss) for the period from January 1 to the current period (thousands of NT$): 116,316. 9. Accumulated net profit (or loss) attributable to owners of the parent from January 1 to the current period (thousands of NT$): 116,316. 10. Basic earnings per share (loss) from January 1 to the current period (NT$): 1.41. 11. Total assets at end of period (thousands of NT$): 9,820,012. 12. Total liabilities at end of period (thousands of NT$): 4,243,460. 13. Equity attributable to owners of the parent at end of period (thousands of NT$): 5,576,552. 14. Other matters to be noted: None.